In this brief article, we present important Dupixent legal and medical information about T-cell lymphoma, which appears to be a Dupixent-related side effect. We start with some of the allegations contained in the lawsuits being filed against the pharmaceutical companies Regeneron Pharmaceuticals, Inc., and Sanofi-Aventis U.S. LLC, based on … [Read more...]
Dupixent Cancer Lawsuits: Legal and Medical Update
We are currently investigating possible Dupixent cancer lawsuits for patients who were diagnosed with a type of cutaneous T-cell lymphoma (CTCL), such as mycosis fungoides (MF) or Sézary syndrome, after they started using Dupixent. The Dupixent cancer lawsuits would be filed against the manufacturers of Dupixent, Sanofi and Regeneron, based on … [Read more...]
Increased Risk of NAION Associated With Ozempic and Mounjaro
A 2025 medical study concluded that there is an increased risk of NAION associated with Ozempic and Mounjaro. In more detail, the researchers considered whether treatment with either Ozempic (semaglutide) or Mounjaro (tirzepatide) is associated with an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) when compared to … [Read more...]
NAION With Mounjaro and Zepbound Being Investigated
The FDA is investigating the possible connection of NAION with Mounjaro and Zepbound, according to “October – December 2024 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)”. During the past year, we have written about the vision loss side effect NAION (non-arteritic … [Read more...]
Semaglutide NAION Side Effect Can Be Part of a Vision Loss AION Diagnosis
The European Medicines Agency (EMA) confirmed the link between the active ingredient in Ozempic, semaglutide, and NAION (non-arteritic anterior ischemic optic neuropathy) in early June 2025. This drug regulator said further that a semaglutide NAION side effect warning would be added to the drug labels for the semaglutide-containing drugs Wegovy, … [Read more...]
Ozempic Vision Loss Lawsuits Against Novo Nordisk
Patients who are filing Ozempic vision loss lawsuits against Novo Nordisk had developed nonarteritic anterior ischemic optic neuropathy (NAION) while using Ozempic. These cases are product liability failure to warn lawsuits filed against the responsible drug company, Novo Nordisk, because the Ozempic drug label does not warn about NAION as a … [Read more...]
Vision Loss Linked to Rybelsus and Ozempic Use by Diabetes Patients
The relatively new drug safety issue of vision loss linked to Rybelsus and Ozempic was the subject of a recent medical study that had this stated Objective, or purpose: “To investigate the association between semaglutide use and the risk of NAION among patients with diabetes.” On March 27, 2025, the JAMA Ophthalmology medical journal published … [Read more...]
Semaglutide: Eyesight Loss From Drug Side Effect NAION
Semaglutide eyesight loss from the drug side effect NAION is being investigated as possible drug injury lawsuits to be filed on behalf of patients against Novo Nordisk, the responsible drug company for Ozempic, Wegovy, and Rybelsus. The active ingredient for each of those three Novo Nordisk drugs is semaglutide. There are a couple of recent … [Read more...]
Depo-Provera Meningioma Increased Risk Warning in Europe
The European Medicines Agency (EMA) recommended a Depo-Provera meningioma increased risk warning in September 2024. One wonders why the FDA has not followed this EMA regulatory action. Therefore, the Depo-Provera drug label in the US still does not include a warning about the meningioma increased risk associated with Depo-Provera. The following … [Read more...]
Why Are There Depo-Provera Brain Tumor Warnings In Europe But Not US?
Depo-Provera brain tumor lawsuits for women who have been diagnosed with intracranial meningioma, a specific type of brain tumor, are being filed against the responsible pharmaceutical companies. A primary focus of these legal cases will be why the Depo-Provera drug label in the US does not include any warnings about the increased risk of this … [Read more...]
- 1
- 2
- 3
- …
- 8
- Next Page »